These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

512 related articles for article (PubMed ID: 21900099)

  • 1. Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach.
    Bladé J; Fernández de Larrea C; Rosiñol L; Cibeira MT; Jiménez R; Powles R
    J Clin Oncol; 2011 Oct; 29(28):3805-12. PubMed ID: 21900099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of extramedullary plasmacytomas on outcomes according to treatment approach in newly diagnosed symptomatic multiple myeloma.
    Lee SE; Kim JH; Jeon YW; Yoon JH; Shin SH; Eom KS; Kim YJ; Kim HJ; Lee S; Cho SG; Lee JW; Min WS; Park CW; Min CK
    Ann Hematol; 2015 Mar; 94(3):445-52. PubMed ID: 25257340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of outcomes after autologous stem cell transplantation between myeloma patients with skeletal and soft tissue plasmacytoma.
    Shin HJ; Kim K; Lee JW; Song MK; Lee JJ; Lee HS; Lee WS; Kim SJ; Chung JS
    Eur J Haematol; 2014 Nov; 93(5):414-21. PubMed ID: 24813053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extramedullary disease in plasma cell myeloma: the iceberg phenomenon.
    Wirk B; Wingard JR; Moreb JS
    Bone Marrow Transplant; 2013 Jan; 48(1):10-8. PubMed ID: 22410751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry.
    Alegre A; Granda A; Martínez-Chamorro C; Díaz-Mediavilla J; Martínez R; García-Laraña J; Lahuerta JJ; Sureda A; Bladé J; de la Rubia J; Fernández-Rañada JM; San Miguel J; ; ;
    Haematologica; 2002 Jun; 87(6):609-14. PubMed ID: 12031917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple myeloma with extramedullary disease.
    Oriol A
    Adv Ther; 2011 Nov; 28 Suppl 7():1-6. PubMed ID: 22105527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasmacytoma relapses in the absence of systemic progression post-high-dose therapy for multiple myeloma.
    Terpos E; Rezvani K; Basu S; Milne AE; Rose PE; Scott GL; Rahemtulla A; Samson D; Apperley JF
    Eur J Haematol; 2005 Nov; 75(5):376-83. PubMed ID: 16191086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations.
    Rosiñol L; Beksac M; Zamagni E; Van de Donk NWCJ; Anderson KC; Badros A; Caers J; Cavo M; Dimopoulos MA; Dispenzieri A; Einsele H; Engelhardt M; Fernández de Larrea C; Gahrton G; Gay F; Hájek R; Hungria V; Jurczyszyn A; Kröger N; Kyle RA; Leal da Costa F; Leleu X; Lentzsch S; Mateos MV; Merlini G; Mohty M; Moreau P; Rasche L; Reece D; Sezer O; Sonneveld P; Usmani SZ; Vanderkerken K; Vesole DH; Waage A; Zweegman S; Richardson PG; Bladé J
    Br J Haematol; 2021 Aug; 194(3):496-507. PubMed ID: 33724461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extramedullary vs medullary relapse after autologous or allogeneic hematopoietic stem cell transplantation (HSCT) in multiple myeloma (MM) and its correlation to clinical outcome.
    Zeiser R; Deschler B; Bertz H; Finke J; Engelhardt M
    Bone Marrow Transplant; 2004 Dec; 34(12):1057-65. PubMed ID: 15516937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extramedullary multiple myeloma escapes the effect of thalidomide.
    Rosiñol L; Cibeira MT; Bladé J; Esteve J; Aymerich M; Rozman M; Segarra M; Cid MC; Filella X; Montserrat E
    Haematologica; 2004 Jul; 89(7):832-6. PubMed ID: 15257935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extensive extramedullary disease in myeloma. An uncommon variant with features of poor prognosis and dedifferentiation.
    Sanal SM; Yaylaci M; Mangold KA; Pantazis CG
    Cancer; 1996 Apr; 77(7):1298-302. PubMed ID: 8608506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytogenetics of extramedullary manifestations in multiple myeloma.
    Billecke L; Murga Penas EM; May AM; Engelhardt M; Nagler A; Leiba M; Schiby G; Kröger N; Zustin J; Marx A; Matschke J; Tiemann M; Goekkurt E; Heidtmann HH; Vettorazzi E; Dierlamm J; Bokemeyer C; Schilling G
    Br J Haematol; 2013 Apr; 161(1):87-94. PubMed ID: 23368088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three cases of bortezomib-resistant multiple myeloma with extramedullary masses.
    Moriuchi M; Ohmachi K; Kojima M; Tsuboi K; Ogawa Y; Nakamura N; Ando K
    Tokai J Exp Clin Med; 2010 Apr; 35(1):17-20. PubMed ID: 21319020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
    Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
    Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paraskeletal and extramedullary plasmacytomas in multiple myeloma at diagnosis and at first relapse: 50-years of experience from an academic institution.
    Jiménez-Segura R; Rosiñol L; Cibeira MT; Fernández de Larrea C; Tovar N; Rodríguez-Lobato LG; Bladé E; Moreno DF; Oliver-Caldés A; Bladé J
    Blood Cancer J; 2022 Sep; 12(9):135. PubMed ID: 36114167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between intracranial plasmacytoma and multiple myeloma: clinicopathological outcome study.
    Schwartz TH; Rhiew R; Isaacson SR; Orazi A; Bruce JN
    Neurosurgery; 2001 Nov; 49(5):1039-44; discussion 1044-5. PubMed ID: 11846895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma cell neoplasms. Review of disease progression and report of a new variant.
    Nolan KD; Mone MC; Nelson EW
    Surg Oncol; 2005 Aug; 14(2):85-90. PubMed ID: 15993050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Graft-versus-myeloma after donor leukocyte infusion: maintenance of marrow remission but extramedullary relapse with plasmacytomas.
    Zomas A; Stefanoudaki K; Fisfis M; Papadaki T; Mehta J
    Bone Marrow Transplant; 1998 Jun; 21(11):1163-5. PubMed ID: 9645583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P53 deletion may drive the clinical evolution and treatment response in multiple myeloma.
    López-Anglada L; Gutiérrez NC; García JL; Mateos MV; Flores T; San Miguel JF
    Eur J Haematol; 2010 Apr; 84(4):359-61. PubMed ID: 20002730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.
    Palumbo A; Attal M; Roussel M
    Clin Cancer Res; 2011 Mar; 17(6):1253-63. PubMed ID: 21411441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.